Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Drinks To Drugs: DyDo Charts Course For Pharma Entry

Executive Summary

A company with its main business in soft drinks and canned coffee might seem an unlikely entrant into the prescription pharma business, but Japan’s DyDo Group maintains it has solid reasons and a robust business plan for what it sees as an important future growth driver.

You may also be interested in...



Asia Deal Watch: India’s Encube Targeted As Private Equity Interest In CDMOs Grows

Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.

Asajes Offers Up Innovative Partnering Model For Asia Development

Asajes Ventures sees itself as offering a unique new mixed business model of venture capital and local development activity for smaller Western companies looking to develop their product or pipeline assets in Japan and China, aided by new opportunities from a rapidly reforming regulatory environment.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.

Topics

Related Companies

UsernamePublicRestriction

Register

SC123046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel